Arcturus Therapeutics reported a quarterly loss of $0.95 per share, better than the Zacks Consensus Estimate of a $1.14 loss. That also marks an improvement from a $0.52 loss per share a year ago. The narrower-than-expected loss is a modest positive for the biotech name and could support the stock modestly.
Arcturus Therapeutics reported a quarterly loss of $0.95 per share, better than the Zacks Consensus Estimate of a $1.14 loss. That also marks an improvement from a $0.52 loss per share a year ago. The narrower-than-expected loss is a modest positive for the biotech name and could support the stock modestly.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
